Memantine Aurobindo

Memantine Hydrochloride, the active ingredient in Memantine Aurobindo, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients.

GNH USA supplies Memantine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function. - Alzheimer’s disease (mild to moderate): improves cognitive performance and daily living activities. - Alzheimer’s disease (moderate to severe): helps maintain functional abilities and slows decline. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with the condition.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Seizures: occurrence of convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening. - Hepatic failure: impaired liver function. - Suicidal thoughts: emergence of depressive or suicidal ideation.

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: assess kidney function and adjust dose if needed. - History of seizures: monitor closely for new seizure activity. - Cardiovascular disease: evaluate risk of arrhythmias. - Concomitant NMDA antagonists: avoid combined use to prevent additive effects. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase adverse effects. - Other NMDA receptor antagonists: combined use can lead to excessive inhibition. - Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits of memantine. - Diuretics: can alter renal clearance and affect drug concentration. - Alcohol: may exacerbate dizziness and CNS depression.